Healthcare Analyst Bodnar holds a conference call with President & CEO Wong and CFO Young to discuss the company’s novel, clinical stage anti-immunoglobulin-E (IgE)monoclonal antibody (mAb), ozureprubart on December 4 at 2 pm. Webcast Link
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics Announces CMO Departure
- Rapt Therapeutics price target raised to $57 from $55 at JPMorgan
- Rapt Therapeutics price target lowered to $56 from $58 at Barclays
- RAPT Therapeutics Advances with Strong Financial Backing
- Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street